Terms ending in 2035
Every in-force patent on Sandoz AG's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,598,718 | Quantification of Misfolded TNFR2:FC In force · Medium confidence | Sandoz AG | In force | Medium confidence | |
| US 10,865,416 | Recombinant Host Cell Engineered to Overexpress Helper Proteins In force · High confidence | Boehringer Ingelheim RCV GmbH & Co. KG, Lonza Ltd., Validogen GmbH and Sandoz AG | In force | High confidence | |
| US 10,127,839 | Apparatus For Simulating The Function Of Human Stomach And/Or Human Intestine Grace period ended Nov 13, 2026 · lapse expected · Low confidence | Sandoz AG | Grace period ended Nov 13, 2026 lapse expected | Low confidence | |
| US 10,189,860 | Novel Hydrates Of Dolutegravir Sodium In force · High confidence | Lek Pharmaceuticals D.D. | In force | High confidence | |
| US 10,590,427 | Recombinant Host Cell for Expressing Proteins of Interest In force · High confidence | Validogen GmbH | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Sandoz AG.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.